Retatrutide 10MG

$90.00

Description
Delivery Details

Description

Retatrutide 10MG

Retatrutide uniquely activates GLP-1, GIP, and glucagon receptors simultaneously, creating synergistic effects:

GLP-1: Reduces hunger via brain signaling; delays stomach emptying.
GIP: Boosts insulin post-meal; improves fat browning (energy-burning).
Glucagon: Increases thermogenesis (calorie burn) and reduces liver fat without raising blood sugar excessively.

Key Advantage at 10 mg: Highest receptor occupancy leads to maximal glucagon-driven fat oxidation. Preclinical data (Nature Medicine, 2022) shows 30–50% greater energy expenditure vs. dual-agonists.

Detailed Clinical Data for 10 mg Dose

From pivotal Phase 2 trials (published NEJM June 2023; n=338 obese/non-diabetic adults):

Dose	% Body Weight Loss (48 weeks)	% with ≥15% Loss	HbA1c Change (T2D trial)	Key Metabolic Improvements
10 mg	-17.5% (obesity); -16.9%** (T2D)	76–81%	-1.8%	↓ Liver fat 82%; ↓ Triglycerides 30%; ↓ BP 6–8 mmHg
4 mg (comparative)	-12.9%	64%	-1.4%	Moderate
Placebo	-1.6%	27%	-0.3%	Minimal
Tirzepatide 15 mg** (benchmark)	~20% (SURMOUNT-1)	57%	-2.3%	Similar but less liver fat reduction

Phase 3 (TRIUMPH-1/2, ongoing): Targeting 88 weeks; interim data suggests >25% loss at 10–12 mg.
72-week extension: 10 mg group maintained -24.2% loss; 90% kept ≥15% off.

Subgroup Benefits:

Liver Disease: 80–90% NAFLD resolution (vs. 20% placebo).
Heart Health: ↓ Waist circumference 18 cm; improved insulin sensitivity.

Administration and Titration Protocol (Trial Standard)

Weekly SC injection (abdomen/thigh/arm). Slow titration minimizes GI side effects:

Week	Dose (mg)
1–4	2.5
5–8	5
9+	10** (maintenance)

Half-life: ~6 days (steady-state by week 4).
Storage: Refrigerate; stable 21 days room temp.

Side Effects Profile (10 mg Specific)

Mostly mild-moderate, peaking during titration (resolve in 80% by week 12).

Adverse Event	Incidence (10 mg)	Severity/Management
Nausea	58%	Mild; antiemetics (ondansetron)
Vomiting	32%	Dose-hold if severe
Diarrhea	25%	Hydration, loperamide
Increased HR** (+10 bpm)	20%	Monitor; resolves post-dose
Serious (rare <2%)	Gallbladder (1.5%), hypoglycemia (T2D)	Stop if pancreatitis suspected

Contraindications: Personal/family medullary thyroid cancer history, MEN2, severe GI disease.

Unofficial 10 mg Products (Compounded/Research Chem)

Common Forms: 10 mg vials (lyophilized powder; reconstitute with bacteriostatic water). ~$200–500/vial (10–20 doses) from sites like Peptide Sciences or Chinese suppliers.
Quality Issues (Verified by 3rd-party labs like Colmaric Analyticals, 2024):

Issue	Prevalence	Risk
<80% Purity	40% of samples	Reduced efficacy/toxins
Bacterial Contamination	15%	Infections
Incorrect Labeling (e.g., actually tirzepatide)	10%	Unexpected effects

DIY Dosing Risks: Overdose → severe dehydration; underdose → no results. No sterility guarantees.

Comparisons and Future Outlook

Drug	Max Dose	Max Weight Loss	Cost (US, approved)	Approval Status
Retatrutide 10 mg	10–12 mg	24–30% (proj.)	TBD (~$1k/month?)	Phase 3 (2026?)
Tirzepatide	15 mg	22%	$1,000/month	Approved
Semaglutide	2.4 mg	15–20%	$1,300/month	Approved

Projections: Lilly aims for obesity + T2D + NASH indications. Patent protection to 2036+.

Final Advice: Experimental—pursue via clinical trials (e.g., Lilly’s site) or wait for approval. Track via Lilly Pipeline or PubMed. Physician oversight essential for any use.

Sources: NEJM (2023), Lancet (2024 Phase 3 updates), FDA trial registry, independent lab reports. Updated Oct 2024.

Delivery Details

2-3 days from the time of purchase to all locations

Order now and enjoy great discounts! We deliver top-quality peptide products straight to you. Fast, reliable, and discreet service. Delivery hours: 10 AM–8 PM daily. Don’t miss out